B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.
B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.